Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy; Unit of Obstetrics and Gynecology, IRCCS S. Matteo Foundation, Viale Golgi 19, 27100 Pavia, Italy.
Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy; Unit of Obstetrics and Gynecology, IRCCS S. Matteo Foundation, Viale Golgi 19, 27100 Pavia, Italy; Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS S. Matteo Foundation, Viale Golgi 19, 27100 Pavia, Italy.
Maturitas. 2024 Dec;190:108129. doi: 10.1016/j.maturitas.2024.108129. Epub 2024 Sep 26.
The shift in paradigm from the belief that endometriosis exclusively affects women of reproductive age has brought attention to its manifestation in postmenopausal patients. Despite this emerging awareness, there remains a dearth of information in the literature regarding postmenopausal endometriosis, with uncertainties surrounding its prevalence, clinical significance, optimal management strategies, and prognosis. Clinical manifestations of endometriosis in menopausal patients lack specificity, with pain onset possible at any stage of life. The primary approach for symptomatic postmenopausal endometriosis continues to be surgical excision, serving both diagnostic and therapeutic purposes while mitigating the risk of coexisting malignancies. Managing the disease in postmenopausal women presents challenges due to possible contraindications for menopausal hormone therapy and the elevated risk of recurrence and malignant transformation. However, conclusive data regarding the appropriateness of menopausal hormone therapy in women with endometriosis or a history of the disease are lacking. Current recommendations lean towards prioritizing combined menopausal hormone therapy formulations or tibolone over estrogen-only therapies due to their potentially higher malignancy risk. The possible increased risk of osteoporosis and cardiovascular disease in postmenopausal women with endometriosis is likely linked to a history of surgical menopause at an earlier age, but more research is warranted. This narrative review summarizes the available literature and provides insights into the intricate connection between endometriosis and menopause, shedding light on pathogenesis, symptoms, oncologic risk, diagnosis, and treatment.
从认为子宫内膜异位症仅影响育龄妇女的观念转变,已经引起了人们对绝经后患者中该病症表现的关注。尽管这种新的认识已经出现,但关于绝经后子宫内膜异位症的文献信息仍然匮乏,其患病率、临床意义、最佳管理策略和预后等方面存在不确定性。绝经后患者的子宫内膜异位症临床表现缺乏特异性,疼痛可能在任何年龄段出现。对于有症状的绝经后子宫内膜异位症,主要的治疗方法仍然是手术切除,既可以起到诊断和治疗的作用,又可以降低同时存在恶性肿瘤的风险。由于绝经激素治疗可能存在禁忌证,以及复发和恶性转化的风险增加,绝经后妇女的疾病管理存在挑战。然而,关于绝经激素治疗在子宫内膜异位症或该疾病病史的女性中的适宜性,缺乏确凿的数据。目前的建议倾向于优先选择联合绝经激素治疗方案或替勃龙,而不是雌激素单独治疗,因为它们的恶性风险可能更高。绝经后患有子宫内膜异位症的女性可能会增加骨质疏松症和心血管疾病的风险,这可能与更早的手术绝经史有关,但还需要更多的研究。本综述总结了现有文献,并深入探讨了子宫内膜异位症与绝经之间的复杂关系,揭示了发病机制、症状、肿瘤风险、诊断和治疗。